Multi-omics AI for precision medicine
in rare diseases and hereditary cancers
Integrating genomics and transcriptomics to make diagnosis faster, more accessible, and more accurate for the 400+ million people with rare diseases and the millions affected by hereditary cancers
Integrated WES/WGS and RNA-Seq data analysis for comprehensive diagnostic profiling
Automated gene prioritization powered by a proprietary AI model
A user-friendly, web-based diagnostic decision support system
Our Flagship Platform
RNA-Seq Analysis
Leverages structured control cohorts across multiple tissue types to identify aberrant splicing events, abnormal gene and transcript expression, and allele-specific expression
Multi-omics Insights
Integrates genomic and transcriptomic (RNA-Seq) data to link genetic variants with functional evidence, enabling more comprehensive interpretation and improved diagnostic yield
AI-Driven Interpretation
Applies PhiTech's proprietary AI algorithm to prioritize disease-causing genes, reducing analysis time and supporting faster, more confident diagnostic decision-making
Customers & Partners
Diagnostic Laboratories
A scalable AI platform that accelerates variant interpretation and improves diagnostic yield across multi-omics testing
Hospitals & Clinics
High-yield diagnostic insights for rare diseases and hereditary cancers, supporting faster diagnostic decision-making
Academic &
Research Centers
Advanced transcriptomic and genomic research capabilities to accelerate translational discovery in precision medicine
Biopharma & CROs
Optimizing drug development with precision biomarker identification and efficient patient stratification
Up to 30% improvement in diagnostic yield
DNA
RNA
AI
Rare Diseases
Hereditary Cancers
10K Distinct Types
of rare and genetic diseases
6+ Years
the average time to diagnosis
60% of Patients
remained undiagnosed
2M+
new cases annually
80% of Patients
at risk not received genetic test
FIGURES & IMPACT
400M Patients
living with a rare disease globally
Rare diseases may be individually rare, but collectively they affect millions. The statistics below highlight the scale of the problem:
~10% of new cancer cases are hereditary,
yet nearly 80% of at-risk patients
never receive genetic testing:
G&M
G&M enables up to a 30% improvement in diagnostic yield:
Latest News
from PhiTech
MAR 8, 2026
NOV 6, 2024
MAR 8, 2024